Roivant (ROIV) and Immunovant (IMVT) announces topline results from proof-of-concept study of IMVT-1402 in cutaneous Lupus Erythematosus

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

US President Trump's support for the ban of diesel exports was seen to "blindside" industry officials, WSJ reports citing sources; lobbyists rushed to register their opposition to the ban

Amazon (AMZN) and Best Buy (BBY) expand Fire TV partnership

Roivant (ROIV) and Immunovant (IMVT) announces topline results from proof-of-concept study of IMVT-1402 in cutaneous Lupus Erythematosus

General Mills (GIS) Q1 2027 (USD): Adj. EPS 0.75 (exp. 0.72), Revenue 4.39bln (exp. 4.35bln). Reaffirms FY27 Adj. EPS view

US MBA Purchase Index (Sep/18) 154.9 (Prev. 156.2)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Immunovant’s proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12.
  • Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet
  • IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies
  • All other clinical development timelines remain on track

Related headlines

The whole workspace, free to try.

Try it free